poisar

Stocks · News reference

Guggenheim Maintains Buy on Illumina, Raises Price Target to $305

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ILMN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million

    Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.

    RHHBYILMNNTRAQGENERRFY
  2. SEC EDGAR

    8-K filing — ILLUMINA, INC. (ILMN)

    Filed: 2026-10-13 AccNo: 0001110803-26-000195 Size: 389 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

    ILMN